GoodRx Holdings, Inc. (GDRX) 10-Year Financial Performance & Capital Metrics

GDRX • • Industrial / General

HealthcareHealthcare ITRevenue Cycle ManagementPatient Financial Services

AboutGoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was incorporated in 2015 and is headquartered in Santa Monica, California.Show more

Revenue $792M +5.6%
EBITDA $135M +67.8%
Net Income $16M +284.8%
EPS (Diluted) 0.04 +293.5%
Gross Margin 93.91% +3.1%
EBITDA Margin 17.09% +58.9%
Operating Margin 8.31% +330.9%
Net Margin 2.07% +275.0%
ROE 2.21% +296.0%
ROIC 6.1% +337.0%
Debt/Equity 0.75 -19.6%
Interest Coverage 1.24 +361.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 15.3%
✓Share count reduced 4.4% through buybacks
✓Trading at only 1.5x book value

✗Weaknesses

✗Profits declining 24.3% over 5 years
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y15.34%

3Y2.05%

TTM1.3%

Profit (Net Income) CAGR

10Y-

5Y-24.33%

3Y-

TTM500.68%

EPS CAGR

10Y-

5Y-19.02%

3Y-

TTM671.79%

ROCE

10Y Avg6%

5Y Avg-5.36%

3Y Avg1.04%

Latest4.82%

Peer Comparison

Patient Financial Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
HQYHealthEquity, Inc.	7.49B	86.94	79.76	20.03%	14.86%	8.99%	4.51%	0.52
GDRXGoodRx Holdings, Inc.	282.66M	2.68	64.11	5.61%	3.97%	5.29%	40.17%	0.75

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	249.52M	388.22M	550.7M	745.42M	766.55M	750.26M	792.32M
Revenue Growth %	-	0.56%	0.42%	0.35%	0.03%	-0.02%	0.06%
Cost of Goods Sold+	6.04M	14.02M	29.59M	46.72M	65.08M	66.92M	48.22M
COGS % of Revenue	0.02%	0.04%	0.05%	0.06%	0.08%	0.09%	0.06%
Gross Profit+	243.49M	374.21M	521.11M	698.71M	701.48M	683.34M	744.11M
Gross Margin %	0.98%	0.96%	0.95%	0.94%	0.92%	0.91%	0.94%
Gross Profit Growth %	-	0.54%	0.39%	0.34%	0%	-0.03%	0.09%
Operating Expenses+	166.24M	234.53M	796.83M	685.3M	699.74M	710.35M	678.26M
OpEx % of Revenue	0.67%	0.6%	1.45%	0.92%	0.91%	0.95%	0.86%
Selling, General & Admin	112.54M	191.66M	716.59M	524.9M	502.42M	466.84M	484.98M
SG&A % of Revenue	0.45%	0.49%	1.3%	0.7%	0.66%	0.62%	0.61%
Research & Development	43.89M	29.3M	61.82M	125.86M	143.14M	135.84M	123.75M
R&D % of Revenue	0.18%	0.08%	0.11%	0.17%	0.19%	0.18%	0.16%
Other Operating Expenses	-7K	13.57M	18.43M	34.54M	54.18M	107.67M	69.54M
Operating Income+	77.25M	139.68M	-275.72M	13.41M	1.74M	-27.01M	65.85M
Operating Margin %	0.31%	0.36%	-0.5%	0.02%	0%	-0.04%	0.08%
Operating Income Growth %	-	0.81%	-2.97%	1.05%	-0.87%	-16.54%	3.44%
EBITDA+	87.06M	153.25M	-257.29M	47.95M	55.91M	80.66M	135.38M
EBITDA Margin %	0.35%	0.39%	-0.47%	0.06%	0.07%	0.11%	0.17%
EBITDA Growth %	-	0.76%	-2.68%	1.19%	0.17%	0.44%	0.68%
D&A (Non-Cash Add-back)	9.81M	13.57M	18.43M	34.54M	54.18M	107.67M	69.54M
EBIT	74.54M	132.55M	-275.54M	13.46M	11.01M	1.16M	84.38M
Net Interest Income+	-22.04M	-48.85M	-27.75M	-23.58M	-24.97M	-24.56M	-29.65M
Interest Income	154K	715K	160K	59K	9.27M	32.17M	23.27M
Interest Expense	22.19M	49.57M	27.91M	23.64M	34.24M	56.73M	52.92M
Other Income/Expense	-24.9M	-56.7M	-27.73M	-23.58M	-24.97M	-28.57M	-34.39M
Pretax Income+	52.35M	82.98M	-303.45M	-10.18M	-23.23M	-55.57M	31.46M
Pretax Margin %	0.21%	0.21%	-0.55%	-0.01%	-0.03%	-0.07%	0.04%
Income Tax+	8.55M	16.93M	-9.83M	15.08M	9.6M	-46.7M	15.07M
Effective Tax Rate %	0.84%	0.8%	0.97%	2.48%	1.41%	0.16%	0.52%
Net Income+	43.79M	66.05M	-293.62M	-25.25M	-32.83M	-8.87M	16.39M
Net Margin %	0.18%	0.17%	-0.53%	-0.03%	-0.04%	-0.01%	0.02%
Net Income Growth %	-	0.51%	-5.45%	0.91%	-0.3%	0.73%	2.85%
Net Income (Continuing)	43.79M	66.05M	-293.62M	-25.25M	-32.83M	-8.87M	16.39M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	0.12	0.12	-1.07	-0.06	-0.08	-0.02	0.04
EPS Growth %	-	0%	-9.92%	0.94%	-0.33%	0.73%	2.94%
EPS (Basic)	0.12	0.12	-1.07	-0.06	-0.08	-0.02	0.04
Diluted Shares Outstanding	362.6M	362.6M	274.7M	409.98M	412.86M	410.31M	392.17M
Basic Shares Outstanding	356.07M	356.07M	274.7M	409.98M	412.86M	410.31M	385.74M
Dividend Payout Ratio	30.74%	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	73.07M	86.58M	1.09B	1.09B	919.69M	872.79M	659.25M
Cash & Short-Term Investments	34.6M	26.05M	971.59M	941.11M	757.16M	672.3M	448.35M
Cash Only	34.6M	26.05M	971.59M	941.11M	757.16M	672.3M	448.35M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	33.36M	55.52M	97.29M	126.41M	121.67M	160.04M	160.83M
Days Sales Outstanding	48.8	52.2	64.49	61.9	57.93	77.86	74.09
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	1.66M	0	0	21.31M	35.1M	15.48M	50.08M
Total Non-Current Assets+	241.72M	300.21M	408.22M	518.8M	684.95M	716.01M	728.81M
Property, Plant & Equipment	988K	34.17M	50.77M	49.32M	55.73M	45.86M	40.46M
Fixed Asset Turnover	252.55x	11.36x	10.85x	15.11x	13.76x	16.36x	19.58x
Goodwill	220.42M	236.22M	261.12M	329.7M	412.12M	410.77M	410.77M
Intangible Assets	18.27M	26.45M	56.72M	133.78M	189.94M	156.34M	176.88M
Long-Term Investments	0	0	0	0	0	15M	15M
Other Non-Current Assets	1.18M	1.16M	2.02M	6.01M	27.16M	22.77M	8.52M
Total Assets+	314.79M	386.8M	1.49B	1.61B	1.6B	1.59B	1.39B
Asset Turnover	0.79x	1.00x	0.37x	0.46x	0.48x	0.47x	0.57x
Asset Growth %	-	0.23%	2.86%	0.08%	-0%	-0.01%	-0.13%
Total Current Liabilities+	16.62M	33.37M	59.55M	81.11M	76.32M	122.56M	123.9M
Accounts Payable	7.2M	7.85M	10.29M	17.5M	17.7M	36.27M	14.14M
Days Payables Outstanding	435.46	204.45	126.95	136.74	99.27	197.79	107.02
Short-Term Debt	5.43M	7.03M	11.57M	7.03M	7.03M	8.79M	5M
Deferred Revenue (Current)	258K	1000K	1000K	1000K	1000K	1000K	0
Other Current Liabilities	2.54M	0	17.23M	0	0	33.82M	69.41M
Current Ratio	4.40x	2.59x	18.24x	13.42x	12.05x	7.12x	5.32x
Quick Ratio	4.40x	2.59x	18.24x	13.42x	12.05x	7.12x	5.32x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.46B	1.44B	723.68M	694.83M	713.48M	704.28M	539.51M
Long-Term Debt	716.81M	663.89M	659.89M	655.86M	651.8M	647.7M	486.71M
Capital Lease Obligations	-737.01M	37.13M	33.47M	33.59M	54.13M	48.4M	46.04M
Deferred Tax Liabilities	3.46M	0	24.48M	244K	0	0	0
Other Non-Current Liabilities	-733.68M	739.98M	5.85M	5.14M	7.56M	8.18M	6.75M
Total Liabilities	1.48B	1.47B	783.23M	775.95M	789.8M	826.84M	663.41M
Total Debt+	722.24M	710.99M	704.92M	702.33M	717.02M	711.07M	543.39M
Net Debt	687.64M	684.94M	-266.67M	-238.78M	-40.14M	38.77M	95.04M
Debt / Equity	-	-	0.99x	0.84x	0.88x	0.93x	0.75x
Debt / EBITDA	8.30x	4.64x	-	14.65x	12.82x	8.82x	4.01x
Net Debt / EBITDA	7.90x	4.47x	-	-4.98x	-0.72x	0.48x	0.70x
Interest Coverage	3.48x	2.82x	-9.88x	0.57x	0.05x	-0.48x	1.24x
Total Equity+	-1.16B	-1.09B	711.36M	831.68M	814.83M	761.96M	724.66M
Equity Growth %	-	0.06%	1.65%	0.17%	-0.02%	-0.06%	-0.05%
Book Value per Share	-3.21	-3.00	2.59	2.03	1.97	1.86	1.85
Total Shareholders' Equity	-1.16B	-1.09B	711.36M	831.68M	814.83M	761.96M	724.66M
Common Stock	451K	460K	39K	40K	40K	40K	38K
Retained Earnings	-1.16B	-1.1B	-1.39B	-1.42B	-1.45B	-1.46B	-1.44B
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-554K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	45.25M	83.29M	131.34M	178.78M	146.78M	138.29M	183.89M
Operating CF Margin %	0.18%	0.21%	0.24%	0.24%	0.19%	0.18%	0.23%
Operating CF Growth %	-	0.84%	0.58%	0.36%	-0.18%	-0.06%	0.33%
Net Income	43.79M	66.05M	-293.62M	-25.25M	-32.83M	-8.87M	16.39M
Depreciation & Amortization	9.81M	13.57M	18.43M	34.54M	54.18M	111.77M	69.54M
Stock-Based Compensation	1.76M	3.75M	397.29M	160.46M	120.23M	104.82M	99.03M
Deferred Taxes	-2.43M	-5.67M	-10.91M	12.85M	-497K	-65.56M	-11.91M
Other Non-Cash Items	4.1M	10.41M	52.62M	7.98M	25.98M	18.07M	8.76M
Working Capital Changes	-11.77M	-4.82M	-32.46M	-11.8M	-20.29M	-21.94M	2.09M
Change in Receivables	-12.84M	-14.52M	-16.14M	-43.95M	1.38M	-26.47M	-2.33M
Change in Inventory	-2.55M	0	0	0	0	0	0
Change in Payables	665K	515K	2.15M	4.21M	-874K	17.46M	-21.24M
Cash from Investing+	-3.46M	-37.05M	-91.62M	-178.73M	-210.5M	-55.77M	-70.35M
Capital Expenditures	-3.46M	-1.43M	-20.55M	-4.57M	-3.97M	-1.04M	0
CapEx % of Revenue	0.01%	0%	0.04%	0.01%	0.01%	0%	0.09%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	-2.65M	-4.32M	-15.27M	-29.89M	-51.25M	-54.72M	-70.35M
Cash from Financing+	-24.73M	-54.78M	905.82M	-30.53M	-120.23M	-167.4M	-337.5M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	-1.35B	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	714.75M	828K	-78.95M	-23.5M	-11.48M	-58.15M	-11.64M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	41.8M	77.54M	95.52M	144.32M	91.57M	82.53M	113.55M
FCF Margin %	0.17%	0.2%	0.17%	0.19%	0.12%	0.11%	0.14%
FCF Growth %	-	0.86%	0.23%	0.51%	-0.37%	-0.1%	0.38%
FCF per Share	0.12	0.21	0.35	0.35	0.22	0.20	0.29
FCF Conversion (FCF/Net Income)	1.03x	1.26x	-0.45x	-7.08x	-4.47x	-15.59x	11.22x
Interest Paid	18.66M	48.44M	24.52M	20.2M	30.7M	48.8M	55.1M
Taxes Paid	11.7M	19.4M	29.23M	18.11M	4.36M	17.24M	23.62M

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-41.28%	-3.27%	-3.99%	-1.12%	2.21%
Return on Invested Capital (ROIC)	-	-	-983.61%	1.94%	0.19%	-2.57%	6.1%
Gross Margin	97.58%	96.39%	94.63%	93.73%	91.51%	91.08%	93.91%
Net Margin	17.55%	17.01%	-53.32%	-3.39%	-4.28%	-1.18%	2.07%
Debt / Equity	-	-	0.99x	0.84x	0.88x	0.93x	0.75x
Interest Coverage	3.48x	2.82x	-9.88x	0.57x	0.05x	-0.48x	1.24x
FCF Conversion	1.03x	1.26x	-0.45x	-7.08x	-4.47x	-15.59x	11.22x
Revenue Growth	-	55.59%	41.85%	35.36%	2.83%	-2.13%	5.61%

Revenue by Segment

	2020	2021	2022	2023	2024
Prescription Transactions Revenue	488.26M	593.36M	550.54M	550.74M	577.55M
Prescription Transactions Revenue Growth	-	21.53%	-7.22%	0.04%	4.87%
Subscription Revenue	-	59.92M	96.17M	94.41M	86.54M
Subscription Revenue Growth	-	-	60.48%	-1.83%	-8.34%
Other Revenue	62.44M	92.14M	20.43M	20.05M	21M
Other Revenue Growth	-	47.56%	-77.83%	-1.83%	4.74%

Frequently Asked Questions

Valuation & Price

GoodRx Holdings, Inc. (GDRX) has a price-to-earnings (P/E) ratio of 64.1x. This suggests investors expect higher future growth.

Growth & Financials

GoodRx Holdings, Inc. (GDRX) reported $800.7M in revenue for fiscal year 2024. This represents a 221% increase from $249.5M in 2018.

GoodRx Holdings, Inc. (GDRX) grew revenue by 5.6% over the past year. This is steady growth.

Yes, GoodRx Holdings, Inc. (GDRX) is profitable, generating $31.8M in net income for fiscal year 2024 (2.1% net margin).

Dividend & Returns

GoodRx Holdings, Inc. (GDRX) has a return on equity (ROE) of 2.2%. This is below average, suggesting room for improvement.

GoodRx Holdings, Inc. (GDRX) generated $86.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

GoodRx Holdings, Inc. (GDRX) 10-Year Financial Performance & Capital Metrics

GDRX • • Industrial / General

HealthcareHealthcare ITRevenue Cycle ManagementPatient Financial Services

Revenue $792M +5.6%
EBITDA $135M +67.8%
Net Income $16M +284.8%
EPS (Diluted) 0.04 +293.5%
Gross Margin 93.91% +3.1%
EBITDA Margin 17.09% +58.9%
Operating Margin 8.31% +330.9%
Net Margin 2.07% +275.0%
ROE 2.21% +296.0%
ROIC 6.1% +337.0%
Debt/Equity 0.75 -19.6%
Interest Coverage 1.24 +361.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 15.3%
✓Share count reduced 4.4% through buybacks
✓Trading at only 1.5x book value

✗Weaknesses

✗Profits declining 24.3% over 5 years
✗Weak momentum: RS Rating 14 (bottom 14%)
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y15.34%

3Y2.05%

TTM1.3%

Profit (Net Income) CAGR

10Y-

5Y-24.33%

3Y-

TTM500.68%

EPS CAGR

10Y-

5Y-19.02%

3Y-

TTM671.79%

ROCE

10Y Avg6%

5Y Avg-5.36%

3Y Avg1.04%

Latest4.82%

Peer Comparison

Patient Financial Services

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
HQYHealthEquity, Inc.	7.49B	86.94	79.76	20.03%	14.86%	8.99%	4.51%	0.52
GDRXGoodRx Holdings, Inc.	282.66M	2.68	64.11	5.61%	3.97%	5.29%	40.17%	0.75

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	249.52M	388.22M	550.7M	745.42M	766.55M	750.26M	792.32M
Revenue Growth %	-	0.56%	0.42%	0.35%	0.03%	-0.02%	0.06%
Cost of Goods Sold+	6.04M	14.02M	29.59M	46.72M	65.08M	66.92M	48.22M
COGS % of Revenue	0.02%	0.04%	0.05%	0.06%	0.08%	0.09%	0.06%
Gross Profit+	243.49M	374.21M	521.11M	698.71M	701.48M	683.34M	744.11M
Gross Margin %	0.98%	0.96%	0.95%	0.94%	0.92%	0.91%	0.94%
Gross Profit Growth %	-	0.54%	0.39%	0.34%	0%	-0.03%	0.09%
Operating Expenses+	166.24M	234.53M	796.83M	685.3M	699.74M	710.35M	678.26M
OpEx % of Revenue	0.67%	0.6%	1.45%	0.92%	0.91%	0.95%	0.86%
Selling, General & Admin	112.54M	191.66M	716.59M	524.9M	502.42M	466.84M	484.98M
SG&A % of Revenue	0.45%	0.49%	1.3%	0.7%	0.66%	0.62%	0.61%
Research & Development	43.89M	29.3M	61.82M	125.86M	143.14M	135.84M	123.75M
R&D % of Revenue	0.18%	0.08%	0.11%	0.17%	0.19%	0.18%	0.16%
Other Operating Expenses	-7K	13.57M	18.43M	34.54M	54.18M	107.67M	69.54M
Operating Income+	77.25M	139.68M	-275.72M	13.41M	1.74M	-27.01M	65.85M
Operating Margin %	0.31%	0.36%	-0.5%	0.02%	0%	-0.04%	0.08%
Operating Income Growth %	-	0.81%	-2.97%	1.05%	-0.87%	-16.54%	3.44%
EBITDA+	87.06M	153.25M	-257.29M	47.95M	55.91M	80.66M	135.38M
EBITDA Margin %	0.35%	0.39%	-0.47%	0.06%	0.07%	0.11%	0.17%
EBITDA Growth %	-	0.76%	-2.68%	1.19%	0.17%	0.44%	0.68%
D&A (Non-Cash Add-back)	9.81M	13.57M	18.43M	34.54M	54.18M	107.67M	69.54M
EBIT	74.54M	132.55M	-275.54M	13.46M	11.01M	1.16M	84.38M
Net Interest Income+	-22.04M	-48.85M	-27.75M	-23.58M	-24.97M	-24.56M	-29.65M
Interest Income	154K	715K	160K	59K	9.27M	32.17M	23.27M
Interest Expense	22.19M	49.57M	27.91M	23.64M	34.24M	56.73M	52.92M
Other Income/Expense	-24.9M	-56.7M	-27.73M	-23.58M	-24.97M	-28.57M	-34.39M
Pretax Income+	52.35M	82.98M	-303.45M	-10.18M	-23.23M	-55.57M	31.46M
Pretax Margin %	0.21%	0.21%	-0.55%	-0.01%	-0.03%	-0.07%	0.04%
Income Tax+	8.55M	16.93M	-9.83M	15.08M	9.6M	-46.7M	15.07M
Effective Tax Rate %	0.84%	0.8%	0.97%	2.48%	1.41%	0.16%	0.52%
Net Income+	43.79M	66.05M	-293.62M	-25.25M	-32.83M	-8.87M	16.39M
Net Margin %	0.18%	0.17%	-0.53%	-0.03%	-0.04%	-0.01%	0.02%
Net Income Growth %	-	0.51%	-5.45%	0.91%	-0.3%	0.73%	2.85%
Net Income (Continuing)	43.79M	66.05M	-293.62M	-25.25M	-32.83M	-8.87M	16.39M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	0.12	0.12	-1.07	-0.06	-0.08	-0.02	0.04
EPS Growth %	-	0%	-9.92%	0.94%	-0.33%	0.73%	2.94%
EPS (Basic)	0.12	0.12	-1.07	-0.06	-0.08	-0.02	0.04
Diluted Shares Outstanding	362.6M	362.6M	274.7M	409.98M	412.86M	410.31M	392.17M
Basic Shares Outstanding	356.07M	356.07M	274.7M	409.98M	412.86M	410.31M	385.74M
Dividend Payout Ratio	30.74%	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	73.07M	86.58M	1.09B	1.09B	919.69M	872.79M	659.25M
Cash & Short-Term Investments	34.6M	26.05M	971.59M	941.11M	757.16M	672.3M	448.35M
Cash Only	34.6M	26.05M	971.59M	941.11M	757.16M	672.3M	448.35M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	33.36M	55.52M	97.29M	126.41M	121.67M	160.04M	160.83M
Days Sales Outstanding	48.8	52.2	64.49	61.9	57.93	77.86	74.09
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	1.66M	0	0	21.31M	35.1M	15.48M	50.08M
Total Non-Current Assets+	241.72M	300.21M	408.22M	518.8M	684.95M	716.01M	728.81M
Property, Plant & Equipment	988K	34.17M	50.77M	49.32M	55.73M	45.86M	40.46M
Fixed Asset Turnover	252.55x	11.36x	10.85x	15.11x	13.76x	16.36x	19.58x
Goodwill	220.42M	236.22M	261.12M	329.7M	412.12M	410.77M	410.77M
Intangible Assets	18.27M	26.45M	56.72M	133.78M	189.94M	156.34M	176.88M
Long-Term Investments	0	0	0	0	0	15M	15M
Other Non-Current Assets	1.18M	1.16M	2.02M	6.01M	27.16M	22.77M	8.52M
Total Assets+	314.79M	386.8M	1.49B	1.61B	1.6B	1.59B	1.39B
Asset Turnover	0.79x	1.00x	0.37x	0.46x	0.48x	0.47x	0.57x
Asset Growth %	-	0.23%	2.86%	0.08%	-0%	-0.01%	-0.13%
Total Current Liabilities+	16.62M	33.37M	59.55M	81.11M	76.32M	122.56M	123.9M
Accounts Payable	7.2M	7.85M	10.29M	17.5M	17.7M	36.27M	14.14M
Days Payables Outstanding	435.46	204.45	126.95	136.74	99.27	197.79	107.02
Short-Term Debt	5.43M	7.03M	11.57M	7.03M	7.03M	8.79M	5M
Deferred Revenue (Current)	258K	1000K	1000K	1000K	1000K	1000K	0
Other Current Liabilities	2.54M	0	17.23M	0	0	33.82M	69.41M
Current Ratio	4.40x	2.59x	18.24x	13.42x	12.05x	7.12x	5.32x
Quick Ratio	4.40x	2.59x	18.24x	13.42x	12.05x	7.12x	5.32x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.46B	1.44B	723.68M	694.83M	713.48M	704.28M	539.51M
Long-Term Debt	716.81M	663.89M	659.89M	655.86M	651.8M	647.7M	486.71M
Capital Lease Obligations	-737.01M	37.13M	33.47M	33.59M	54.13M	48.4M	46.04M
Deferred Tax Liabilities	3.46M	0	24.48M	244K	0	0	0
Other Non-Current Liabilities	-733.68M	739.98M	5.85M	5.14M	7.56M	8.18M	6.75M
Total Liabilities	1.48B	1.47B	783.23M	775.95M	789.8M	826.84M	663.41M
Total Debt+	722.24M	710.99M	704.92M	702.33M	717.02M	711.07M	543.39M
Net Debt	687.64M	684.94M	-266.67M	-238.78M	-40.14M	38.77M	95.04M
Debt / Equity	-	-	0.99x	0.84x	0.88x	0.93x	0.75x
Debt / EBITDA	8.30x	4.64x	-	14.65x	12.82x	8.82x	4.01x
Net Debt / EBITDA	7.90x	4.47x	-	-4.98x	-0.72x	0.48x	0.70x
Interest Coverage	3.48x	2.82x	-9.88x	0.57x	0.05x	-0.48x	1.24x
Total Equity+	-1.16B	-1.09B	711.36M	831.68M	814.83M	761.96M	724.66M
Equity Growth %	-	0.06%	1.65%	0.17%	-0.02%	-0.06%	-0.05%
Book Value per Share	-3.21	-3.00	2.59	2.03	1.97	1.86	1.85
Total Shareholders' Equity	-1.16B	-1.09B	711.36M	831.68M	814.83M	761.96M	724.66M
Common Stock	451K	460K	39K	40K	40K	40K	38K
Retained Earnings	-1.16B	-1.1B	-1.39B	-1.42B	-1.45B	-1.46B	-1.44B
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-554K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	45.25M	83.29M	131.34M	178.78M	146.78M	138.29M	183.89M
Operating CF Margin %	0.18%	0.21%	0.24%	0.24%	0.19%	0.18%	0.23%
Operating CF Growth %	-	0.84%	0.58%	0.36%	-0.18%	-0.06%	0.33%
Net Income	43.79M	66.05M	-293.62M	-25.25M	-32.83M	-8.87M	16.39M
Depreciation & Amortization	9.81M	13.57M	18.43M	34.54M	54.18M	111.77M	69.54M
Stock-Based Compensation	1.76M	3.75M	397.29M	160.46M	120.23M	104.82M	99.03M
Deferred Taxes	-2.43M	-5.67M	-10.91M	12.85M	-497K	-65.56M	-11.91M
Other Non-Cash Items	4.1M	10.41M	52.62M	7.98M	25.98M	18.07M	8.76M
Working Capital Changes	-11.77M	-4.82M	-32.46M	-11.8M	-20.29M	-21.94M	2.09M
Change in Receivables	-12.84M	-14.52M	-16.14M	-43.95M	1.38M	-26.47M	-2.33M
Change in Inventory	-2.55M	0	0	0	0	0	0
Change in Payables	665K	515K	2.15M	4.21M	-874K	17.46M	-21.24M
Cash from Investing+	-3.46M	-37.05M	-91.62M	-178.73M	-210.5M	-55.77M	-70.35M
Capital Expenditures	-3.46M	-1.43M	-20.55M	-4.57M	-3.97M	-1.04M	0
CapEx % of Revenue	0.01%	0%	0.04%	0.01%	0.01%	0%	0.09%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	-2.65M	-4.32M	-15.27M	-29.89M	-51.25M	-54.72M	-70.35M
Cash from Financing+	-24.73M	-54.78M	905.82M	-30.53M	-120.23M	-167.4M	-337.5M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	-1.35B	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	714.75M	828K	-78.95M	-23.5M	-11.48M	-58.15M	-11.64M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	41.8M	77.54M	95.52M	144.32M	91.57M	82.53M	113.55M
FCF Margin %	0.17%	0.2%	0.17%	0.19%	0.12%	0.11%	0.14%
FCF Growth %	-	0.86%	0.23%	0.51%	-0.37%	-0.1%	0.38%
FCF per Share	0.12	0.21	0.35	0.35	0.22	0.20	0.29
FCF Conversion (FCF/Net Income)	1.03x	1.26x	-0.45x	-7.08x	-4.47x	-15.59x	11.22x
Interest Paid	18.66M	48.44M	24.52M	20.2M	30.7M	48.8M	55.1M
Taxes Paid	11.7M	19.4M	29.23M	18.11M	4.36M	17.24M	23.62M

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-41.28%	-3.27%	-3.99%	-1.12%	2.21%
Return on Invested Capital (ROIC)	-	-	-983.61%	1.94%	0.19%	-2.57%	6.1%
Gross Margin	97.58%	96.39%	94.63%	93.73%	91.51%	91.08%	93.91%
Net Margin	17.55%	17.01%	-53.32%	-3.39%	-4.28%	-1.18%	2.07%
Debt / Equity	-	-	0.99x	0.84x	0.88x	0.93x	0.75x
Interest Coverage	3.48x	2.82x	-9.88x	0.57x	0.05x	-0.48x	1.24x
FCF Conversion	1.03x	1.26x	-0.45x	-7.08x	-4.47x	-15.59x	11.22x
Revenue Growth	-	55.59%	41.85%	35.36%	2.83%	-2.13%	5.61%

Revenue by Segment

	2020	2021	2022	2023	2024
Prescription Transactions Revenue	488.26M	593.36M	550.54M	550.74M	577.55M
Prescription Transactions Revenue Growth	-	21.53%	-7.22%	0.04%	4.87%
Subscription Revenue	-	59.92M	96.17M	94.41M	86.54M
Subscription Revenue Growth	-	-	60.48%	-1.83%	-8.34%
Other Revenue	62.44M	92.14M	20.43M	20.05M	21M
Other Revenue Growth	-	47.56%	-77.83%	-1.83%	4.74%

Frequently Asked Questions

Valuation & Price

GoodRx Holdings, Inc. (GDRX) has a price-to-earnings (P/E) ratio of 64.1x. This suggests investors expect higher future growth.

Growth & Financials

GoodRx Holdings, Inc. (GDRX) reported $800.7M in revenue for fiscal year 2024. This represents a 221% increase from $249.5M in 2018.

GoodRx Holdings, Inc. (GDRX) grew revenue by 5.6% over the past year. This is steady growth.

Yes, GoodRx Holdings, Inc. (GDRX) is profitable, generating $31.8M in net income for fiscal year 2024 (2.1% net margin).

Dividend & Returns

GoodRx Holdings, Inc. (GDRX) has a return on equity (ROE) of 2.2%. This is below average, suggesting room for improvement.

GoodRx Holdings, Inc. (GDRX) generated $86.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.